We read with great interest the paper by Dong et al. ([@bib1]) describing the clinical course of 4 patients with pre-existing heart failure infected by COVID-19. The authors convey the message that patients with cardiovascular disease are more prone to adverse outcomes due to direct inflammatory damage of the heart ([@bib1]).

These patients had a severe end-stage dilated cardiomyopathy (mean left ventricular end-diastolic diameter of 8 ± 2.2 cm) and markedly impaired ventricular function (mean left ventricular ejection fraction \[LVEF\] of 25 ± 3.8%) ([@bib1]). It is not clear whether they had been hospitalized for manifestations of the severe acute respiratory syndrome-related coronavirus-2 (SARSr-CoV-2) infection or for other causes, as the symptoms described were fatigue and mild cough, common to both respiratory infection and heart failure.

All patients had acute myocardial injury, defined as rise and fall of cardiac troponin (cTn). As reference, the authors cite 2 papers showing epidemiological features and clinical aspects of COVID-19 patients that are not focused on cardiac involvement ([@bib1]). Other reports, including 416 and 144 patients respectively and focused on acute cardiac injury (demonstrating a relationship between elevated cTn, up to 28-fold increase of normal values and an adverse outcome), were not considered ([@bib2],[@bib3])

Although the authors claim they provided "a stronger evidence of myocardial injury in COVID-19," a direct link between the cardiac injury and COVID-19 appears rather uncertain in the population described ([@bib1]). Patients with long-lasting heart failure and severely compromised functional status are burdened by high mortality in the course of any infection, even in the absence of a direct viral damage. COVID-19 may have contributed to worsening of heart failure to some extent, even if the reported chest computed tomography scan and the maintenance of spontaneous respiration do suggest a mild infection form. Finally, the lack of electrocardiographic and echocardiographic data (with the exception of left ventricular ejection fraction) and even more nuclear magnetic resonance data, necessary to characterize myocardial tissue structure and function, greatly limit the informative contribution of this paper. Additionally, the specific causes of death were not specified by the authors.

As the effect of SARS-CoV-2 on cardiac function are still undetermined, all information gathered from the clinical front line should always be adequately contextualized and sufficiently detailed. Caution should be used in defining causal relationships, especially when acute clinical conditions may be due to pre-existing conditions, making it difficult to disentangle from the viral effects.
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